Clinical Trial Update: Open-Label Surufatinib in European Patients With NET [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial of surufatinib in European patients with neuroendocrine tumors was terminated, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Pulmonary Neuroendocrine Tumor
• Small Intestine Neuroendocrine Tumor

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchmed | Conditions: Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung | Phase 2 | Status: TERMINATED | Results posted: 2025-07-25